(Q35798941)

English

Tumor infiltrating CD8(+) T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinoma

scientific article published on 22 May 2015

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Tumor infiltrating CD8(+) T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

toll-like receptor

0 references

renal cell carcinoma

1 reference

based on heuristic

inferred from title

Arja Jukkola-Vuorinen

5

object named as

Arja Jukkola-Vuorinen

0 references

Kirsi-Maria Haapasaari

11

object named as

Kirsi-Maria Haapasaari

0 references

6

object named as

Ylermi Soini

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Markku H Vaarala

object named as

Markku H Vaarala

8

0 references

Joonas Kauppila

object named as

Joonas H Kauppila

2

0 references

Petri Lehenkari

object named as

Petri Lehenkari

4

0 references

author name string

Mikko Mella

1

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Peeter Karihtala

3

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Päivi Auvinen

7

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Hanna Ronkainen

9

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Saila Kauppila

10

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Kirsi-Maria Haapasaari

11

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Katri S Vuopala

12

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Katri S Selander

13

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

publication date

22 May 2015

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

e1002726

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

describes a project that uses

1 reference

Europe PubMed Central

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC4485740/fullTextXML

based on heuristic

inferred from PubMed Central ID database lookup

Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Immunogenic cell death in radiation therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

DNA from dead cancer cells induces TLR9-mediated invasion and inflammation in living cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

New insights into the role of the immune microenvironment in breast carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Expression of Toll-like receptor-9 is associated with poor progression-free survival in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Cell-death-associated molecular patterns as determinants of cancer immunogenicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Intratumoral alterations of dendritic-cell differentiation and CD8(+) T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Immunogenic cell death in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Cancer immunotherapy comes of age

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Toll-like receptor 9 is a novel biomarker for esophageal squamous cell dysplasia and squamous cell carcinoma progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Human tumor cells killed by anthracyclines induce a tumor-specific immune response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Triple negative breast cancer: from molecular portrait to therapeutic intervention.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

JAK3/STAT5/6 pathway alterations are associated with immune deviation in CD8 T cells in renal cell carcinoma patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

The immunogenicity of tumor cell death

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Toll-like receptor function and signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

A Toll-like receptor recognizes bacterial DNA

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

11 July 2018

Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

25 September 2018

Presence of CD3+ tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

25 September 2018

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

25 September 2018

High DGK-α and disabled MAPK pathways cause dysfunction of human tumor-infiltrating CD8+ T cells that is reversible by pharmacologic intervention.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

25 September 2018

Bridging innate and adaptive immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

25 September 2018

Increased Toll-like receptor 9 expression indicates adverse prognosis in oesophageal adenocarcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

25 September 2018

Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

25 September 2018

Toll-like receptor 9 ligands enhance mesenchymal stem cell invasion and expression of matrix metalloprotease-13.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

25 September 2018

Toll-like receptor-9 expression is inversely correlated with estrogen receptor status in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

25 September 2018

Increased expression of Toll-like receptors 4 and 9 in human lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

25 September 2018

Expression of TLR9 within human glioblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

25 September 2018

Therapeutic implications of KIT in melanoma

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2014.1002726

21 January 2018

Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4485740

23 October 2018

An improved image analysis method for cell counting lends credibility to the prognostic significance of T cells in colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26155410

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TLR9 and the recognition of self and non-self nucleic acids

1 reference

https://pubmed.ncbi.nlm.nih.gov/26155410

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnostic and therapeutic implications of tumor-infiltrating lymphocytes in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26155410

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/26155410

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphocyte infiltrates as a prognostic variable in female breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26155410

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/26155410

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/26155410

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1080/2162402X.2014.1002726

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35798941&oldid=1702372478"